BU-NOT-SET

CONTACT US
Modified release fixed dose combination product with two poorly soluble drug substances
  • Drug product
pellets
Case study
Patient centricity during drug development and commercialisation
  • Drug product
Eyes
Insight
10 considerations to kick-start your drug development journey
  • Drug product
Eyes
Insight
Guidance for start-ups on drug development
  • Drug product
Eyes
Insight
Drug development for start-ups
  • Drug product
  • Drug substance
Test tubes
White paper
Optimising environmental sustainability
  • Sustainability
Eyes
Insight
Adapting to deal with the COVID-19 pandemic
  • Industry trends
Eyes
Insight
On Drug Delivery – Sustainability Q&A
  • Sustainability
Eyes
Insight
Optimising analytical chemistry to improve speed to market
  • Analytical chemistry
Man lab
Insight
White paper
  • Biologics
Product Quality in the Advanced Therapies Manufacturing
Insight
  • Biologics
Navigating ATMP fill and finish complexities
Insight
  • Biologics
The power of analytics and AI in the era of continuous RNA manufacturing
Insight
  • Biologics
Reimagining the RNA manufacturing space: An interview with ReciBioPharm’s leaders
Insight
  • Biologics
Unlocking the potential of mRNA: Inside ReciBioPharm's Watertown site
Insight
  • Biologics
Industry 5.0 in action: AI-driven continuous manufacturing for RNA therapeutics
Insight
  • Drug product
  • Manufacturing
Choosing the optimal container format for sterile drug products
Insight
  • Manufacturing
FDA inspection success at Recipharm’s site in Bengaluru, India
Fact sheet
  • Drug product
  • Manufacturing
Lyophilisation Services